Proficio Capital Partners LLC Takes Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Proficio Capital Partners LLC purchased a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 31,492 shares of the biotechnology company’s stock, valued at approximately $3,829,000.

Several other institutional investors and hedge funds have also modified their holdings of SRPT. Manchester Capital Management LLC raised its stake in Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its holdings in shares of Sarepta Therapeutics by 169.6% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 156 shares during the last quarter. Sunbelt Securities Inc. grew its holdings in shares of Sarepta Therapeutics by 446.2% during the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 232 shares during the last quarter. Huntington National Bank increased its position in Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 175 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. bought a new position in Sarepta Therapeutics in the 4th quarter valued at approximately $36,000. 86.68% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on SRPT. StockNews.com downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Piper Sandler lowered their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. Scotiabank started coverage on Sarepta Therapeutics in a research note on Friday, March 7th. They set a “sector perform” rating and a $105.00 price target on the stock. HC Wainwright reaffirmed a “sell” rating and issued a $75.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, February 27th. Finally, Royal Bank of Canada dropped their price objective on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating for the company in a report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $170.41.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares of the company’s stock, valued at $2,771,187.68. This trade represents a 8.22 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Up 4.3 %

Shares of Sarepta Therapeutics stock opened at $101.35 on Tuesday. The stock’s 50-day moving average is $111.20 and its 200 day moving average is $119.57. Sarepta Therapeutics, Inc. has a one year low of $97.06 and a one year high of $173.25. The firm has a market cap of $9.83 billion, a price-to-earnings ratio of 81.08 and a beta of 0.79. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.